ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Letrozole Cuts Risk Of Breast Cancer Recurrence Even After Tamoxifen Use

March 28, 2008

Breast Cancer Coalition Seeks Continued DOD Funding For Research

July 2, 1993

In Brief: DCT Board Rejects Move to Count Individual P01 Projects Toward The NIH Total Of 5,000 Grants

June 24, 1983

Advocates Ask Genentech To Release FDA Letter On Avastin For Breast Cancer.

September 29, 2006

NCCN Admits Two New Member Institutions

March 22, 2013

Facilities Survey: $2.5 Billion Will Be Required From 1986-1990, With NCI’s Share At $678 Million

April 12, 1985